Clinical Trials Browser

Phase 3 × Neuroendocrine Tumors × lutetium Lu 177 dotatate × Clear all

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Phase 3 Active not recruiting

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

Neuroendocrine Tumors

NCT01842165 2022-11-10

LUMEN

Phase 3 Completed

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Phase 3 Completed

231 enrolled 16 charts 2 FDA

Neuroendocrine Tumors

NCT01860742 2016-04-05

CASTOR

Phase 3 Withdrawn

Neuroendocrine Tumors